CAR-T cell therapy provides a targeted method to eliminate these pathogenic populations; for instance, CD19-directed CAR-T cells have shown promise in refractory SLE by depleting autoreactive B cells and promoting an immune reset [13]. This evidence concerns the gene CD19 and systemic lupus erythematosus.